Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Big Movers News: Biodel Inc (BIOD)’s Big News, Supernus Pharmaceuticals Inc (SUPN)’s Spike

Editor’s Note: Biodel Inc (NASDAQ:BIOD), Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

Biodel PT Raised to $9.00 (BIOD) (Mideast Time)
Biodel had its price target increased by JMP Securities from $6.00 to $9.00 in a research report sent to investors on Thursday morning, StockRatingsNetwork.com reports. Shares of Biodel Inc (NASDAQ:BIOD) traded up 12.08% during mid-day trading on Thursday, hitting $5.335. The stock had a trading volume of 1,185,247 shares. Biodel has a one year low of $2.13 and a one year high of $6.08. The stock has a 50-day moving average of $4.56 and a 200-day moving average of $3.52. The company’s market cap is $100.8 million.

Hedge Fund Strategies

Supernus shares jump on epilepsy drug approval (MSN Money)
Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) jumped Monday after the company said that its epilepsy treatment was approved by government regulators. The Rockville, Md.-based company said that it received a final approval letter from the Food and Drug Administration for Trokendi XR, an extended-release treatment for epilepsy that is taken once daily. Shares rose 62 cents, or 9.3 percent, to $7.26 Monday afternoon. Through Friday, the share had gained 49 percent from a 52-week low of $4.45 in April.

Our BioPharma Catalyst Watch List (Proactive Investors USA & Canada)
Biodel Inc (NASDAQ:BIOD) is a biopharmaceutical company that focuses on the development and specialization of treatments for diabetes. Biodel’s leading drug candidate is BIOD-123, which is an ultra-rapid acting insulin formulation. Biodel has recently been gaining a lot of attention because it has a market cap of under $100M, while the global diabetes market is worth over $10B. Biodel is expecting to release results from a Phase II trial in the third quarter of 2013.

Supernus Gets FDA Approval for Extended-Release Epilepsy Treatment Trokendi XR (Wall Street Journal)
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) said the U.S. Food and Drug Administration gave final approval for its extended-release epilepsy treatment, which the specialty drug maker expects to roll out over the next few weeks. The latest approval is for Trokendi XR, a once-a-day formulation of topiramate. The FDA also granted a waiver for certain pediatric study requirements and a deferral for submission of post-marketing pediatric pharmacokinetic assessments that are due in 2019 followed by clinical assessments in 2025.

Loading Comments...